# US 2013/0157929 A1 · Glucagon analogues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157929 A1
- Document ID: US20130157929A1
- Status: Published application
- Kind: A1
- Application number: 13/704,299
- Filed: 2011-06-24
- Published: 2013-06-20
- Earliest claimed: 2010-06-24
- Assignees: Zealand Pharma A/S
- Inventors: Ditte Riber; Eddi Meier
- Web page: https://patentgrep.com/patent/US20130157929A1

## CPC

- C07K 14/605: Glucagons
- A61K 38/26: Glucagons
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/48: of the pancreatic hormones
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides materials and methods for promoting weight loss or preventing weight gain and for treating diabetes and associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptide compounds effective in such methods. The compounds may mediate their effect by having, for example, increased selectivity for the GLP-1 receptor compared to human glucagon.

## Claims

### Claim 1

A compound having the formula:
R1—Z—R2
wherein
R1 is H, C1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl;
R2 is OH or NH2; and
Z is a peptide having the formula I:
(I)
(SEQ ID NO: 85)
His-X2-X3-X4-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-
Tyr-Leu-X15-Ser-X17-Ala-Ala-X20-X21-Phe-Val-X24-
Trp-Leu-X27-X28-Ala;
wherein
X2 is Aib, Ser or Gly;
X3 is Gln, Glu, Gly, His, Phe, Leu, Trp, Tyr, Val, Arg, Ala, Ser, Ile, Pro, Hph, Hse, Cit, 1-NaI or 3-(heterocyclyl)alanine;
X4 is Gly, Ala, D-Ala, Val, Aib, Leu, D-Leu, Pro, Glu, Phe, D-Phe, Arg or Lys;
X15 is Asp or Glu;
X17 is Arg or X;
X20 is Arg, His or X;
X21 is Asp or Glu;
X24 is Ala or X;
X27 is Leu or X;
X28 is Arg or X;
wherein each residue X is independently selected from the group consisting of Glu, Lys, Ser, Cys, Dbu, Dpr and Orn;
and wherein the side-chain of at least one amino acid residue X is optionally conjugated to a lipophilic substituent having the formula:
(i) Z1, wherein Z1 is a lipophilic moiety conjugated directly to the side chain of X; or
(ii) Z1Z2, wherein Z1 is a lipophilic moiety, Z2 is a spacer, and Z1 is conjugated to the side chain of X via Z2;
with the proviso that if X3 is Gln, then X4 is not Gly.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein one or more of said residues X is independently selected from Lys, Glu, Dbu, Dpr and Orn.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein:
X17 is selected from Lys and Cys;
X20 is selected from His, Lys, Arg and Cys;
X24 is selected from Lys, Glu and Ala;
X27 is selected from Leu and Lys; and/or
X28 is selected from Ser, Arg and Lys.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein said peptide of formula I includes one or more of the following combinations of residues:
X2 is Aib and X17 is Lys;
X2 is Aib and X17 is Cys;
X2 is Aib and X20 is Cys;
X2 is Aib and X28 is Lys;
X17 is Lys and X20 is Lys;
X17 is Lys and X21 is Asp;
X17 is Lys and X24 is Glu;
X17 is Lys and X27 is Leu;
X17 is Lys and X27 is Lys;
X17 is Lys and X28 is Ser;
X17 is Lys and X28 is Arg;
X20 is Lys and X27 is Leu;
X21 is Asp and X27 is Leu;
X17 is Lys, X24 is Glu and X28 is Arg;
X17 is Lys, X24 is Glu and X28 is Lys;
X17 is Lys, X27 is Leu and X28 is Ser;
X17 is Lys, X27 is Leu and X28 is Arg;
X20 is Lys, X24 is Glu and X27 is Leu;
X20 is Lys, X27 is Leu and X28 is Ser;
X20 is Lys, X27 is Leu and X28 is Arg;
X17 is Lys, X20 is His, X24 is Glu and X28 is Ser;
X17 is Lys, X20 is Lys, X24 is Glu and X27 is Leu; or
X17 is Cys, X20 is Lys, X24 is Glu and X27 is Leu.

### Claim 5 (depends on 1)

A compound according to claim 1, wherein said peptide of formula I contains only one amino acid residue X.

### Claim 6 (depends on 5)

A compound according to claim 5, wherein said peptide of formula I contains only one Lys residue, only one Cys residue or only one Glu residue, and wherein said lipophilic substituent is conjugated to that residue.

### Claim 7 (depends on 1)

A compound according to claim 1, wherein the peptide sequence of formula I comprises one or more intramolecular bridges.

### Claim 8 (depends on 7)

A compound according to claim 7, wherein said intramolecular bridge is formed between the side-chains of two amino acid residues which are separated by three amino acids in the linear amino acid sequence of formula I.

### Claim 9 (depends on 8)

A compound according to claim 8, wherein said intramolecular bridge is formed between the side-chains of amino acid residue pairs 17 and 21, 20 and 24, or 24 and 28.

### Claim 10 (depends on 7)

A compound according to claim 7, wherein said intramolecular bridge is a salt bridge or a lactam ring.

### Claim 11 (depends on 7)

A compound according to claim 7, wherein the intramolecular bridge involves a pair of residues wherein:
X17 is Arg and X21 is Glu;
X17 is Lys and X21 is Glu;
X17 is Arg and X21 is Asp;
X17 is Lys and X21 is Asp;
X20 is Glu and X24 is Lys;
X20 is Lys and X24 is Glu;
X20 is Arg and X24 is Glu;
X24 is Glu and X28 is Lys;
X24 is Glu and X28 is Arg; or
X24 is Lys and X28 is Glu.

### Claim 12 (depends on 1)

A compound according to claim 1, wherein the compound has just one lipophilic substituent, at position 17, 20, 24, 27 or 28, preferably at position 17 or 20, particularly at position 17.

### Claim 13 (depends on 1)

A compound according to claim 1, wherein the compound has precisely two lipophilic substituents, each conjugated to a respective amino acid residue at one of positions 17, 20, 24, 27 or 28.

### Claim 14 (depends on 13)

A compound according to claim 13, wherein the compound has lipophilic substituents on respective amino acid residues at positions 17 and 20, 17 and 24, 17 and 27, or 17 and 28; at 20 and 24, 20 and 27, or 20 and 28; at 24 and 27, or 24 and 28; or at 27 and 28.

### Claim 15 (depends on 1)

A compound according to claim 1, wherein said peptide of formula I has an amino acid sequence selected from the group consisting of:
(SEQ ID NO: 1)
H-Aib-EGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 2)
H-Aib-HGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 3)
H-Aib-QATFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 4)
H-Aib-QVTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 5)
HGQ-Aib-TFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 6)
HGEGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 7)
HSQ-Aib-TFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 8)
H-Aib-QLTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 9)
H-Aib-QPTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 10)
H-Aib-QETFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 11)
H-Aib-Q-Aib-TFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 12)
H-Aib-QFTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 13)
H-Aib-FGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 14)
H-Aib-Q-DPhe-TFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 15)
H-Aib-QRTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 16)
H-Aib-LGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 17)
H-Aib-Hph-GTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 18)
H-Aib-WGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 19)
H-Aib-YGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 20)
H-Aib-VGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 21)
H-Aib-QKTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 22)
H-Aib-RGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 23)
H-Aib-AGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 24)
H-Aib-SGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 25)
H-Aib-IGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 26)
H-Aib-GGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 27)
H-Aib-PGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 28)
H-Aib-HGTFTSDYSKYLDSKAAHEFVEWLLEA;
(SEQ ID NO: 29)
H-Aib-Cit-GTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 30)
H-Aib-Q-DAla-TFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 31)
H-Aib-Hse-GTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 32)
H-Aib-Q-DLeu-TFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 33)
H-Aib-HGTFTSDYSKYLESKAAEEFVEWLLEA;
(SEQ ID NO: 34)
H-Aib-1Nal-GTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 35)
H-Aib-[3-(2-furyl)alanyl]-GTFTSDYSKYLDSKAAHDFVEW
LLSA;
(SEQ ID NO: 36)
H-Aib-[3-(4-thiazolyl)alanyl]-GTFTSDYSKYLDSKAAHD
FVEWLLSA;
(SEQ ID NO: 37)
H-Aib-[3-(3-pyridyl)alanyl]-GTFTSDYSKYLDSKAAHDFV
EWLLSA;
(SEQ ID NO: 38)
H-Aib-[3-(4-pyridyl)alanyl]-GTFTSDYSKYLDSKAAHDFV
EWLLSA;
(SEQ ID NO: 39)
H-Aib-[3-(2-thienyl)alanyl]-GTFTSDYSKYLDSKAAHDFV
EWLLSA;
(SEQ ID NO: 40)
H-Aib-[3-(3-thienyl)alanyl]-GTFTSDYSKYLDSKAAHDFV
EWLLSA;
(SEQ ID NO: 41)
H-Aib-[3-(1-pyrazolyl)alanyl]-GTFTSDYSKYLDSKAAHD
FVEWLLSA;
and
(SEQ ID NO: 42)
H-Aib-[3-(1,2,4-triazol-1-yl)alanyl]-GTFTSDYSKYL
DSKAAHDFVEWLLSA.

### Claim 16 (depends on 15)

A compound according to claim 15, wherein said peptide of formula I has an amino acid sequence selected from the group consisting of:
(SEQ ID NO: 2)
H-Aib-HGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 6)
HGEGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 8)
H-Aib-QLTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 13)
H-Aib-FGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 14)
H-Aib-Q-DPhe-TFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 16)
H-Aib-LGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 19)
H-Aib-YGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 20)
H-Aib-VGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 23)
H-Aib-AGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 24)
H-Aib-SGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 25)
H-Aib-IGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 26)
H-Aib-GGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 27)
H-Aib-PGTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 28)
H-Aib-HGTFTSDYSKYLDSKAAHEFVEWLLEA;
(SEQ ID NO: 29)
H-Aib-Cit-GTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 30)
H-Aib-Q-DAla-TFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 31)
H-Aib-Hse-GTFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 32)
H-Aib-Q-DLeu-TFTSDYSKYLDSKAAHDFVEWLLSA;
(SEQ ID NO: 33)
H-Aib-HGTFTSDYSKYLESKAAEEFVEWLLEA;
(SEQ ID NO: 35)
H-Aib-[3-(2-furyl)alanyl]-GTFTSDYSKYLDSKAAHDFVE
WLLSA;
(SEQ ID NO: 36)
H-Aib-[3-(4-thiazolyl)alanyl]-GTFTSDYSKYLDSKAAH
DFVEWLLSA;
(SEQ ID NO: 37)
H-Aib-[3-(3-pyridyl)alanyl]-GTFTSDYSKYLDSKAAHDF
VEWLLSA;
(SEQ ID NO: 39)
H-Aib-[3-(2-thienyl)alanyl]-GTFTSDYSKYLDSKAAHDF
VEWLLSA;
(SEQ ID NO: 40)
H-Aib-[3-(3-thienyl)alanyl]-GTFTSDYSKYLDSKAAHDF
VEWLLSA;
(SEQ ID NO: 41)
H-Aib-[3-(1-pyrazolyl)alanyl]-GTFTSDYSKYLDSKAAH
DFVEWLLSA;
and
(SEQ ID NO: 42)
H-Aib-[3-(1,2,4-triazol-1-yl)alanyl]-GTFTSDYSKY
LDSKAAHDFVEWLLSA.

### Claim 17 (depends on 1)

A compound according to claim 1, wherein said peptide of formula I has an amino acid sequence selected from the group consisting of:
(SEQ ID NO: 44)
H-Aib-HGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 48)
HGEGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 50)
H-Aib-QLTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 55)
H-Aib-FGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 56)
H-Aib-Q-DPhe-TFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 58)
H-Aib-LGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 61)
H-Aib-YGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 62)
H-Aib-VGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 65)
H-Aib-AGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 66)
H-Aib-SGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 67)
H-Aib-IGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 68)
H-Aib-GGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 69)
H-Aib-PGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 70)
H-Aib-HGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHEFVEWLLEA;
(SEQ ID NO: 71)
H-Aib-Cit-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 72)
H-Aib-Q-DAla-TFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 73)
H-Aib-Hse-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 74)
H-Aib-Q-DLeu-TFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 75)
H-Aib-HGTFTSDYSKYLESK(hexadecanoyl-isoGlu)-AAEEFVEWLLEA;
(SEQ ID NO: 77)
H-Aib-[3-(2-furyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 78)
H-Aib-[3-(4-thiazolyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 79)
H-Aib-[3-(3-pyridyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 81)
H-Aib-[3-(2-thienyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 82)
H-Aib-[3-(3-thienyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
(SEQ ID NO: 83)
H-Aib-[3-(1-pyrazolyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA;
and
(SEQ ID NO: 84)
H-Aib-[3-(1,2,4-triazol-1-yl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA.

### Claim 18 (depends on 1)

A compound according to claim 1, selected from the group consisting of:
(SEQ ID NO: 44)
H-H-Aib-HGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 48)
H-HGEGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 50)
H-H-Aib-QLTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 55)
H-H-Aib-FGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 56)
H-H-Aib-Q-DPhe-TFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 58)
H-H-Aib-LGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 61)
H-H-Aib-YGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 62)
H-H-Aib-VGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 65)
H-H-Aib-AGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 66)
H-H-Aib-SGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 67)
H-H-Aib-IGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 68)
H-H-Aib-GGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 69)
H-H-Aib-PGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 70)
H-H-Aib-HGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHEFVEWLLEA-NH2;
(SEQ ID NO: 71)
H-H-Aib-Cit-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 72)
H-H-Aib-Q-DAla-TFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 73)
H-H-Aib-Hse-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 74)
H-H-Aib-Q-DLeu-TFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 75)
H-H-Aib-HGTFTSDYSKYLESK(hexadecanoyl-isoGlu)-AAEEFVEWLLEA-NH2;
(SEQ ID NO: 77)
H-H-Aib-[3-(2-furyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 78)
H-H-Aib-[3-(4-thiazolyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 79)
H-H-Aib-[3-(3-pyridyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 81)
H-H-Aib-[3-(2-thienyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 82)
H-H-Aib-[3-(3-thienyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 83)
H-H-Aib-[3-(1-pyrazolyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
and
(SEQ ID NO: 84)
H-H-Aib-[3-(1,2,4-triazol-1-yl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2.

### Claim 19 (depends on 1)

A compound according to claim 1, wherein X3 is selected among Gln, His, Ile, Tyr, Pro, Hse, 3-(4-thiazolyl)alanyl, 3-(3-pyridyl)alanyl, 3-(2-thienyl)alanyl, 3-(3-thienyl)alanyl and 3-(1,2,4-triazol-1-yl)alanyl.

### Claim 20 (depends on 19)

A compound according to claim 19, wherein X4 is selected among Gly, D-Ala, D-Leu and D-Phe.

### Claim 21 (depends on 1)

A compound according to claim 1, wherein X3 is selected among Glu, Gly, Leu, Val, Ala, Ser, Cit, 3-(2-furyl)alanyl and 3-(1-pyrazolyl)alanyl.

### Claim 22 (depends on 21)

A compound according to claim 21, wherein X4 is Gly.

### Claim 23 (depends on 19)

A compound according to claim 19, selected from the group consisting of:
(SEQ ID NO: 44)
H-H-Aib-HGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 67)
H-H-Aib-IGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 56)
H-H-Aib-Q-DPhe-TFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 61)
H-H-Aib-YGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 69)
H-H-Aib-PGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 70)
H-H-Aib-HGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHEFVEWLLEA-NH2;
(SEQ ID NO: 72)
H-H-Aib-Q-DAla-TFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 73)
H-H-Aib-Hse-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 74)
H-H-Aib-Q-DLeu-TFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 75)
H-H-Aib-HGTFTSDYSKYLESK(hexadecanoyl-isoGlu)-AAEEFVEWLLEA-NH2;
(SEQ ID NO: 78)
H-H-Aib-[3-(4-thiazolyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 79)
H-H-Aib-[3-(3-pyridyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 81)
H-H-Aib-[3-(2-thienyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 82)
H-H-Aib-[3-(3-thienyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
and
(SEQ ID NO: 84)
H-H-Aib-[3-(1,2,4-triazol-1-yl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2.

### Claim 24 (depends on 21)

A compound according to claim 21, selected from the group consisting of:
(SEQ ID NO: 48)
H-HGEGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 58)
H-H-Aib-LGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 62)
H-H-Aib-VGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 65)
H-H-Aib-AGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 66)
H-H-Aib-SGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 68)
H-H-Aib-GGTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 71)
H-H-Aib-Cit-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
(SEQ ID NO: 83)
H-H-Aib-[3-(1-pyrazolyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2;
and
(SEQ ID NO: 77)
H-H-Aib-[3-(2-furyl)alanyl]-GTFTSDYSKYLDSK(hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH2.

### Claim 25 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt or derivative thereof, together with a pharmaceutically acceptable carrier.

### Claim at position 26

26-29. (canceled)

### Claim 30 (depends on 1)

A method of preventing weight gain or promoting weight loss in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound according to claim 1.

### Claim 31 (depends on 1)

A method of improving circulating glucose levels, glucose tolerance and/or circulating cholesterol levels, lowering circulating LDL levels, and/or increasing HDL/LDL ratio in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound according to claim 1.

### Claim 32 (depends on 1)

A method of treating of a condition caused or characterized by excess body weight in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound according to claim 1.

### Claim 33 (depends on 31)

The method according to claim 31, wherein said compound is administered as part of a combination therapy together with an agent for treatment of diabetes, obesity, dyslipidaemia, or hypertension.

### Claim 34 (depends on 33)

The method according to claim 33, wherein said agent for treatment of diabetes is metformin, a sulfonylurea, a glinide, a DPP-IV inhibitor, a glitazone, insulin, or an insulin analogue.

### Claim 35 (depends on 33)

The method according to claim 33, wherein said agent for treatment of obesity is a glucagon-like peptide receptor 1 agonist, peptide YY or an analogue thereof, a cannabinoid receptor 1 antagonist, a lipase inhibitor, a melanocortin receptor 4 agonist, or a melanin concentrating hormone receptor 1 antagonist.

### Claim 36 (depends on 33)

The method according to claim 33, wherein said agent for treatment of hypertension is an angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, a diuretic, a beta-blocker, or a calcium channel blocker.

### Claim 37 (depends on 33)

The or method according to claim 33, wherein said agent for treatment of dyslipidaemia is a statin, a fibrate, a niacin, or a cholesterol absorption inhibitor.

### Claim 38 (depends on 32)

The method according to claim 32, wherein said compound is administered as part of a combination therapy together with an agent for treatment of diabetes, obesity, dyslipidaemia, or hypertension.

### Claim 39 (depends on 38)

The method according to claim 38, wherein said agent for treatment of diabetes is metformin, a sulfonylurea, a glinide, a DPP-IV inhibitor, a glitazone, insulin, or an insulin analogue.

### Claim 40 (depends on 38)

The method according to claim 38, wherein said agent for treatment of obesity is a glucagon-like peptide receptor 1 agonist, peptide YY or an analogue thereof, a cannabinoid receptor 1 antagonist, a lipase inhibitor, a melanocortin receptor 4 agonist, or a melanin concentrating hormone receptor 1 antagonist.

### Claim 41 (depends on 38)

The method according to claim 38, wherein said agent for treatment of hypertension is an angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, a diuretic, a beta-blocker, or a calcium channel blocker.

### Claim 42 (depends on 38)

The method according to claim 38, wherein said agent for treatment of dyslipidaemia is a statin, a fibrate, a niacin, or a cholesterol absorption inhibitor.

### Claim 43 (depends on 32)

The method according to claim 32, wherein said condition caused or characterized by excess body weight is selected from the group consisting of: obesity, morbid obesity, obesity-linked inflammation, obesity-linked gallbladder disease, obesity-induced sleep apnea, pre-diabetes, insulin resistance, glucose intolerance, type 2 diabetes, type I diabetes, hypertension, atherogenic dyslipidaemia, atherosclerois, arteriosclerosis, coronary heart disease, peripheral artery disease, stroke, or microvascular disease.
